Impact of circulating tumor cell (CTC) nucleus size on outcomes with abiraterone acetate (AA) therapy in men with metastatic castration-resistant prostate cancer (mCRPC)

被引：2
|
作者：
Gill, David Michael
Agarwal, Neeraj
Hahn, Andrew W.
Johnson, Eric
Poole, Austin
Carroll, Emma
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.253
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
253
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Chromosomal instability (CIN) in circulating tumor cells (CTC) predicts for taxane sensitivity in metastatic castration-resistant prostate cancer (mCRPC).
    Keegan, Niamh M.
    Arfe, Andrea
    Barnett, Ethan
    Cohn, Erica Dayan
    Zhao, Jimmy
    Carbone, Emily
    Zanone, Michelle
    Anderson, Amanda
    Wenstrup, Rick
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Independent assessment of TP53 and PTEN as predictors of response to enzalutamide (ENZ) or abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC).
    Hahn, Andrew W.
    Rathi, Nityam
    Gill, David Michael
    VanAlstine, Sidney
    Poole, Austin
    Agarwal, Neeraj
    Maughan, Benjamin Louis
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [43] Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy.
    Sonpavde, Guru
    Nagy, Rebecca J.
    Sartor, A. Oliver
    Pond, Gregory Russell
    Gourdin, Theodore Stewart
    Nandagopal, Lakshminarayanan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [44] Molecular characterization of circulating tumor cells (CTC) and CTC subpopulations in progressive metastatic castration resistant prostate cancer (mCRPC).
    Dittamore, Ryan
    Louw, Jessica
    Krupa, Rachel
    Anand, Aseem
    Danila, Daniel Costin
    Arslan, Zaina
    Bales, Natalee
    Marrinucci, Dena
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [45] Results of a phase II trial of abiraterone acetate (AA) combined with dutasteride (DUT) for men with metastatic castration resistant prostate cancer (mCRPC).
    McKay, Rana R.
    Werner, Lillian
    Zukotynski, Katherine A.
    Domachevsky, Liran
    Elfiky, Aymen
    Pomerantz, Mark M.
    Bubley, Glenn J.
    Montgomery, Robert B.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [46] Unique patterns of the selection and change in circulating tumor cell (CTC) phenotypes and genotypes by drug class in metastatic castration-resistant prostate cancer (mCRPC).
    Scher, Howard I.
    Schonhoft, Joseph
    Graf, Ryon P.
    Dago, Angel E.
    Lee, Jerry
    Sutton, Ramsay
    Schreiber, Nicole A.
    Hullings, Melanie
    Jendrisak, Adam
    Wang, Yipeng
    Landers, Mark Andrew
    Dittamore, Ryan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] CK- and small nuclear size circulating tumor cell (CTCs) phenotypes in metastatic castration-resistant prostate cancer (mCRPC)
    Ferraldeschi, Roberta
    McDaniel, Andrew
    Krupa, Rachel
    Louw, Jessica
    Tucker, Eric
    Bales, Natalee
    Marrinucci, Dena
    Riisnaes, Ruth
    Mateo, Joaquin
    Dittamore, Ryan
    De Bono, Johann Sebastian
    Tomlins, Scott A.
    Attard, Gerhardt
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [48] Evaluation of a composite biomarker panel including circulating tumor cell (CTC) enumeration as a surrogate for survival in metastatic castration-resistant prostate cancer (mCRPC)
    Scher, H. I.
    Heller, G.
    Molina, A.
    Attard, G.
    McCormack, R.
    Riisnaes, R.
    Kheoh, T.
    Fleisher, M.
    Buyse, M.
    De Bono, J. S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S679 - S679
  • [49] Plasma circulating tumor DNA (ctDNA) based clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)
    Kohli, Manish
    Tan, Winston
    Zheng, Tiantian
    Wang, Amy
    Huo, Yelia
    Montesinos, Carlos
    Wong, Calvin
    Du, Pan
    Jia, Shidong
    Yu, Jianjun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [50] Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC).
    Halabi, Susan
    Dutta, Sandipan
    Chi, Kim N.
    Tangen, Catherine M.
    Petrylak, Daniel Peter
    Araujo, John C.
    Fizazi, Karim
    Quinn, David I.
    Higano, Celestia S.
    Tannock, Ian
    Small, Eric Jay
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345